Praluent (alirocumab) — Blue Cross Blue Shield of Kansas
homozygous familial hypercholesterolemia (HoFH)
Preferred products
- Repatha (evolocumab)
Initial criteria
- Diagnosis of HoFH confirmed by ONE of the following: genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes at the LDLR, Apo-B, PCSK9, or LDLRAP1 genes; OR ≥2 such variants at different loci